## Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS Telephone +44 (0)1932 336911

## **Post Authorisation Assessments**

## Versiguard Rabies Suspension for Injection Vm 42058/5113

•	06 November 2023	To reduce the minimum release titre for the finished
		product potency ELISA test.
		To upgrade the product information according to new
	40.14 0000	QRD templates v 9.0.
•	18 May 2023	Change in batch size of active substance.
•	07 December 2022	Replace in vivo potency test with in vitro antigen capture assay.
•	03 June 2021	Changes in the manufacturing process of the active substance.
•	23 April 2021	Deletion of a manufacturing site for a supplier of a
		starting material.
		Submission of an updated Ph. Eur. TSE certificate of
		suitability for a starting material from an already
		approved manufacturer.
		Updating of the product information according to the latest QRD template.
•	07 August 2020	Renewal - UK as CMS.
•	01 November 2019	Change in the address of the marketing authorisation
		holder from Zoetis UK Limited, 5th Floor, 6 St. Andrew
		Street, London, EC4A 3AE to Zoetis UK Limited, 1st
		Floor, Birchwood Building, Springfield Drive,
		Leatherhead, Surrey, KT22 7LP.
•	25 September 2018	Change in the contact details of the QPPV of an existing
	05 December 2017	pharmacovigilance system as described in the DDPS.  Change to part of the (primary) packaging material not in
•		contact with the finished product formulation.
•	24 February 2017	Deletion of a pack size(s) of the finished product.
		Change in the number of units (e.g. tablets*, ampoules*,
		etc.) in a pack outside the range of the currently
	05 January 2017	approved pack sizes of the finished product.  Update to Section 4.8 of the SPC.
•	21 July 2016	Change in the SPC, labelling or package leaflet due to
•	,	new data.
•	05 April 2016	Addition of a new in-process test and limit applied during
		the manufacture of the active substance.
		Change(s) in the manufacturing process of the active
		substance. Change(s) in the manufacturing process of the active
		Change(s) in the manufacturing process of the active substance.
		Change(s) in the manufacturing process of the active
		substance.
	1	<del></del>

•	30 March 2016	New manufacturer of material for which an assessment is required of viral safety and/or TSE risk.  New/updated certificate from an already-approved/new manufacturer.
•	15 March 2016	Change in the invented name of the veterinary medicinal product.